基于国家专利数据库探讨中药复方治疗免疫性血小板减少症用药规律

doi:10.20047/j.issn1673-7210.2023.06.28

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (2048 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the medication and prescription rules of the traditional Chinese medicine compound patent in the treatment of immune thrombocytopenia (ITP) based on the national patent database. Methods The Chinese medicine compound patents for treating ITP published in the National Patent Database were searched, and the search period was from the establishment of the database to May 1, 2022. The traditional Chinese medicine inheritance auxiliary platform V2.5 was used, and the frequency analysis, attribute analysis, association rules, and improved mutual information method as well as the complex system entropy clustering algorithm were performed in order to analyze and visualize the four natures and five flavors, meridian-returning efficacy, and prescriptions, and medication rules. Results A total of 78 traditional Chinese medicine compound patent were included. There were 218 kinds of Chinese herbs, and the top four with high frequency were milkvetch root, unprocessed rehmannia root, tree peony root bark, hairyvein agrimonia herb. The nature of drugs were mainly cold, and others were warm and calm; the five flavors were mainly sweet and bitter, followed by pungent; the liver, kidney and spleen meridians were in majority; there were 12 core combinations and six new prescriptions. Conclusion Traditional Chinese medicine compound are commonly used in the treatment of ITP by invigorating the qi, strengthening the spleen, nourishing the kidney, filling the essence, cooling the blood, promoting the blood circulation, and stopping the bleeding. At the same time, different core drug combinations are selected according to the pathogenesis, deficiency and physical characteristics to improve clinical efficacy.

Key words： Immune thrombocytopenia National patent Medication rule Data mining

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yang ZHU Wenwei LI Xiaojing REN Zirui

Cite this article:

LI Yang ZHU Wenwei LI Xiaojing REN Zirui. Study the medication rules of traditional Chinese medicine compound in the treatment of immune thrombocytopenia based on national patent database[J]. 中国医药导报, 2023, 20(6): 123-127.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.06.28 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I6/123

[1] Lee J，Lee J，Lee H，et al. Epidemiology and management of primary immune thrombocytopenia： A nationwide population-based study in Korea [J]. Thromb Res，2017，155（5）：86-91.
[2] 侯明，胡豫.成人原发免疫性血小板减少症诊断与治疗中国指南（2020年版）[J].中华血液学杂志，2020，41（8）：617-623.
[3] 王明镜，全日城，丁晓庆，等.益气摄血方治疗气不摄血证免疫性血小板减少症多中心、随机、双盲、对照研究[J].中国中西医结合杂志，2020，40（8）：929-934.
[4] 国家药典委员会.中华人民共和国药典[S].一部.北京：中国医药科技出版社，2020：347.
[5] 国家中医药管理局《中华本草》编委会.中华本草[M].上海：上海科学技术出版社，1999.
[6] 南京中医药大学.中药大辞典[M].上海：上海科学技术出版社，2014.
[7] 钟赣生.中药学[S].北京：中国中医药出版社，2016.
[8] 蓝海，侯丽，郎海燕，等.常见血液病的中医分类与命名[J].中医杂志，2019，60（9）：750-753，778.
[9] 储真真，李娜，陈信义，等.特发性血小板减少性紫癜中医药治疗探讨[J].中华中医药杂志，2012，27（5）：1340- 1342.
[10] 陈一清.血小板减少性紫癜辨证施治规律若干问题探要[J].中医药学刊，2005，23（8）：1457-1459.
[11] 朱文伟，陈信义，周永明.成人原发免疫性血小板减少症中医诊治专家共识[J].中华中医药杂志，2022，37（4）：2129-2133.
[12] 丁晓庆，苏伟.免疫性血小板减少性紫癜中医证候分析[J].北京中医药大学学报（中医临床版），2011，18（6）：20-22.
[13] Abuelsaad AS. Supplementation with Astragalus polysaccharides alters Aeromonas-induced tissue-specific cellular immune response [J]. Microb Pathog，2014，66：48-56.
[14] 李勇森，韩孟伊，陈冰霞，等.黄芪对小鼠淋巴细胞及其表面分子的调节作用[J].免疫学杂志，2020，36（1）：52- 57.
[15] 李承德，周文宾，孙艳，等.黄芪多糖对哮喘大鼠Th17/ Treg细胞因子及肺部炎症的影响[J].中国药理学通报，2013，29（9）：1275-1278.
[16] 王志江，魏国栋，马思缇.地黄多糖的化学和药理作用研究进展[J].中国实验方剂学杂志，2015，21（16）：231- 235.
[17] 谢剑琳，张振秋，梁朔，等.HPLC波长切换法同时测定大黄、牡丹皮药对提取物中11个成分的含量[J].药物分析杂志，2013，33（1）：103-107.
[18] 廖晖，Linda KB，David NL.12味止血中药对脂多糖诱导小鼠巨噬细胞产生一氧化氮的抑制作用[J].中国药房，2007，18（9）：649-651.
[19] 孙静.仙鹤草不同成分促进小鼠化疗后血小板减少作用研究[J].中医药信息，2013，30（2）：17-19.
[20] Liu J，Wei J，Wang C，et al. The combination of Radix Astragali and Radix Angelicae Sinensis attenuates the IFN-γ-induced immune destruction of hematopoiesis in bone marrow cells [J]. BMC Complement Altern Med，2019， 19（1）：35-36.
[21] 姜云耀，刘楠，胡晓梅，等.基于网络药理学方法探讨八珍汤治疗ITP的作用机制[J].世界科学技术-中医药现代化，2020，22（9）：3142-3149.
[22] 李大军.柯微君主任医师治疗特发性血小板减少性紫癜的经验[J].中国中医急症，2013，22（4）：585-586.
[23] 何风，李明子，袁彬，等.墨旱莲水煎剂对卡铂致小鼠血小板减少的治疗研究[J].中医药学报，2012，40（1）：30- 32.
[24] 高雅婷，包素珍，张永军.花生红衣下调Bax、Bak表达防治化疗后血小板减少症的研究[J].中华中医药杂志，2018，33（9）：3883-3886.
[25] 刘婧依，刘岐焕.升血小板胶囊联合花生衣提取液治疗特发性血小板减少性紫癜患者临床效果观察[J].临床血液学杂志，2018，31（6）：445-448.
[26] 周莉，张馨慧，何柳婷，等.T细胞组套检测对原发性免疫性血小板减少症病情预判及治疗药物选择的指导应用[J].中国临床研究，2021，34（9）：1194-1198.
[27] 汪琼，汪勇，吴玉玲.外周血CD4+T细胞计数对免疫性血小板减少症患者药物治疗效果评估作用分析[J].中国医药导报，2022，19（23）：121-124.
[28] 朱文伟，鲍计章，周永明.原发免疫性血小板减少症“承制从势”论[J].上海中医药杂志，2022，56（1）：15-18.
[29] 叶放，陶帅，徐吉敏，等.周仲瑛教授应用犀角地黄汤临床经验要素数据挖掘分析[J].中华中医药杂志，2010， 25（10）：1577-1579.